Drug Trial Radar · NCT04802759
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
316
Planned (sponsor's estimate)
Start
Jun 22, 2021
Primary completion
May 30, 2029
Study completion May 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER+, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib, or neratinib). Cohort 3 will focus on inoperable, locally advanced or metastatic, ER+, HER2-negative, PIK3CA-mutated breast cancer with resistance to adjuvant endocrine therapy.
Conditions
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions
GiredestrantDrug
30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
AbemaciclibDrug
150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
IpatasertibDrug
400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
InavolisibDrug
9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
RibociclibDrug
600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
EverolimusDrug
10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
SamuraciclibDrug
360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
PH FDC SCDrug
On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
PalbociclibDrug
125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
AtezolizumabDrug
840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Objective Response, Defined as a Complete or Partial Response, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1)Time frame: From Baseline until disease progression (up to 6 years)
- Number of Participants with Adverse Events, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)Time frame: From Baseline until 30 days after the last dose of study drug (up to 6 years)
Locations
32 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
University of California, San Francisco (UCSF)
San Francisco, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Santa Monica, California · Recruiting
Stanford Cancer Institute (SCI)
Stanford, California · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Regional Cancer Care Associates LLC (RCCA) - Freehold Location
Freehold, New Jersey · Withdrawn
Regional Cancer Care Associates LLC ? Howell Division
Howell Township, New Jersey · Withdrawn
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania · Withdrawn
West Cancer Center
Germantown, Tennessee · Recruiting
Flinders Medical Centre
Bedford Park, South Australia, Australia · Recruiting
Peninsula Health-Frankston Hospital
Frankston, Victoria, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research Limited
Nedlands, Western Australia, Australia · Recruiting
Rambam Medical Center
Haifa, Israel · Recruiting
Hadassah Ein Karem Hospital
Jerusalem, Israel · Recruiting
Rabin MC
Petah Tikva, Israel · Recruiting
The Chaim Sheba Medical Center
Ramat Gan, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Assuta Medical Centers
Tel Aviv, Israel · Recruiting
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel · Recruiting
National Cancer Center
Goyang-si, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Hospital Universitario Vall d Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Recruiting
Centro Integral Oncológico Clara Campal Ensayos Clínicos START
Madrid, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.